Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:algal metabolite
go back to main search page
Accession:CHEBI:84735 term browser browse the term
Definition:Any eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
Synonyms:related_synonym: algal metabolites



show annotations for term's descendants           Sort by:
1,2-dihexadecanoyl-sn-glycero-3-phosphocholine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PLCG1 phospholipase C gamma 1 decreases activity
multiple interactions
EXP 1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein
dipalmitoylphosphatidic acid inhibits the reaction [1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein]
CTD PMID:2001791 NCBI chr24:29,198,536...29,213,899
Ensembl chr24:29,198,556...29,214,714
JBrowse link
1-stearoyl-2-arachidonoylphosphatidic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PLCG1 phospholipase C gamma 1 increases activity EXP 1-stearoyl-2-arachidonoylphosphatidic acid results in increased activity of PLCG1 protein CTD PMID:2001791 NCBI chr24:29,198,536...29,213,899
Ensembl chr24:29,198,556...29,214,714
JBrowse link
2-hydroxypropanoic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SCT secretin decreases abundance EXP SCT protein results in decreased abundance of Lactic Acid CTD PMID:2418308
3',5'-cyclic AMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G P2RY2 purinergic receptor P2Y2 multiple interactions EXP [Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP] CTD PMID:10604969 NCBI chr21:24,987,568...25,009,754
Ensembl chr21:24,992,848...24,996,059
JBrowse link
3'-CMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CDIPT CDP-diacylglycerol--inositol 3-phosphatidyltransferase multiple interactions EXP [delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Hexachlorocyclohexane affects the activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate CTD PMID:2579070 NCBI chr 6:17,910,141...17,914,573
Ensembl chr 6:17,910,192...17,914,653
JBrowse link
3-isobutyl-1-methyl-7H-xanthine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CFTR CF transmembrane conductance regulator multiple interactions EXP [1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein CTD PMID:15161604 NCBI chr14:56,290,417...56,452,919
Ensembl chr14:56,290,275...56,453,977
JBrowse link
4-nitrophenyl phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ALPI alkaline phosphatase, intestinal increases chemical synthesis EXP ALPI protein results in increased chemical synthesis of nitrophenylphosphate CTD PMID:1495895 NCBI chr25:44,107,418...44,110,947 JBrowse link
5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G P2RY2 purinergic receptor P2Y2 multiple interactions EXP pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP] CTD PMID:10604969 NCBI chr21:24,987,568...25,009,754
Ensembl chr21:24,992,848...24,996,059
JBrowse link
8-(4-chlorophenylthio)-cAMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CFTR CF transmembrane conductance regulator multiple interactions EXP [1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein CTD PMID:15161604 NCBI chr14:56,290,417...56,452,919
Ensembl chr14:56,290,275...56,453,977
JBrowse link
acetylsalicylic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PTGS1 prostaglandin-endoperoxide synthase 1 decreases activity EXP Aspirin results in decreased activity of PTGS1 protein alternative form CTD PMID:12242329 NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
JBrowse link
acyclovir term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AVP arginine vasopressin decreases activity EXP Acyclovir results in decreased activity of AVP protein CTD PMID:2724137 NCBI chr24:18,183,057...18,184,827
Ensembl chr24:18,183,057...18,184,883
JBrowse link
cyclophosphamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP2B6 cytochrome P450 2B11 increases hydroxylation EXP CYP2B6 protein results in increased hydroxylation of Cyclophosphamide CTD PMID:16546968 NCBI chr 1:112,817,561...112,833,294
Ensembl chr 1:112,816,502...112,833,293
JBrowse link
cytidine 5'-monophosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CDIPT CDP-diacylglycerol--inositol 3-phosphatidyltransferase multiple interactions EXP [delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Hexachlorocyclohexane affects the activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate CTD PMID:2579070 NCBI chr 6:17,910,141...17,914,573
Ensembl chr 6:17,910,192...17,914,653
JBrowse link
dichlorvos term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACHE acetylcholinesterase decreases activity EXP Dichlorvos results in decreased activity of ACHE protein CTD PMID:89824 PMID:3627083 NCBI chr 6:8,874,747...8,879,926
Ensembl chr 6:8,873,584...8,879,702
JBrowse link
G BCHE butyrylcholinesterase decreases activity EXP Dichlorvos results in decreased activity of BCHE protein CTD PMID:3627083 PMID:4631366 NCBI chr34:30,912,632...30,977,624
Ensembl chr34:30,912,632...30,977,583
JBrowse link
dihexadecanoyl phosphatidic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PLCG1 phospholipase C gamma 1 multiple interactions
increases activity
EXP dipalmitoylphosphatidic acid inhibits the reaction [1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein]
dipalmitoylphosphatidic acid results in increased activity of PLCG1 protein
CTD PMID:2001791 NCBI chr24:29,198,536...29,213,899
Ensembl chr24:29,198,556...29,214,714
JBrowse link
diisopropyl fluorophosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BCHE butyrylcholinesterase decreases activity EXP Isoflurophate results in decreased activity of BCHE protein CTD PMID:4631366 NCBI chr34:30,912,632...30,977,624
Ensembl chr34:30,912,632...30,977,583
JBrowse link
dimyristoyl phosphatidic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PLCG1 phospholipase C gamma 1 increases activity EXP dimyristoylphosphatidic acid results in increased activity of PLCG1 protein CTD PMID:2001791 NCBI chr24:29,198,536...29,213,899
Ensembl chr24:29,198,556...29,214,714
JBrowse link
dioleoyl phosphatidic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PLCG1 phospholipase C gamma 1 increases activity EXP dioleoylphosphatidic acid results in increased activity of PLCG1 protein CTD PMID:2001791 NCBI chr24:29,198,536...29,213,899
Ensembl chr24:29,198,556...29,214,714
JBrowse link
nitroglycerin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G REN renin decreases activity EXP Nitroglycerin results in decreased activity of REN protein CTD PMID:8640982 NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
JBrowse link
ochratoxin A term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACTA2 actin alpha 2, smooth muscle multiple interactions
increases expression
EXP CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of ACTA2 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]
ochratoxin A results in increased expression of ACTA2 mRNA; ochratoxin A results in increased expression of ACTA2 protein
CTD PMID:33543323 NCBI chr26:38,700,434...38,714,915
Ensembl chr26:38,700,480...38,711,753
JBrowse link
G B9D2 B9 domain containing 2 increases expression
multiple interactions
EXP ochratoxin A results in increased expression of TGFB1 mRNA; ochratoxin A results in increased expression of TGFB1 protein
CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of TGFB1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]
CTD PMID:33543323 NCBI chr 1:112,621,832...112,627,726
Ensembl chr 1:112,621,633...112,643,885
JBrowse link
G GSDMD gasdermin D multiple interactions
increases expression
EXP CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]
ochratoxin A results in increased expression of GSDMD mRNA; ochratoxin A results in increased expression of GSDMD protein
CTD PMID:33543323 NCBI chr13:37,221,219...37,226,912
Ensembl chr13:37,193,022...37,228,360
JBrowse link
G IL18 interleukin 18 multiple interactions
increases expression
EXP CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL18 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA] CTD PMID:33543323 NCBI chr 5:20,972,742...20,995,327
Ensembl chr 5:20,972,871...20,995,348
JBrowse link
G IL1B interleukin 1 beta multiple interactions
increases expression
EXP CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL1B mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]
ochratoxin A results in increased expression of IL1B mRNA; ochratoxin A results in increased expression of IL1B protein
CTD PMID:33543323 NCBI chr17:37,019,329...37,033,388
Ensembl chr17:37,019,329...37,024,458
JBrowse link
G IL6 interleukin 6 increases secretion
increases expression
EXP ochratoxin A results in increased secretion of IL6 protein
ochratoxin A results in increased expression of IL6 mRNA
CTD PMID:33543323 NCBI chr14:36,474,268...36,478,519
Ensembl chr14:36,473,394...36,478,519
JBrowse link
G NLRP3 NLR family pyrin domain containing 3 multiple interactions
increases expression
EXP N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of CASP1 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of VIM protein]
ochratoxin A results in increased expression of NLRP3 mRNA; ochratoxin A results in increased expression of NLRP3 protein
CTD PMID:33543323 NCBI chr 8:251,776...313,290
Ensembl chr 8:253,407...313,059
JBrowse link
G PYCARD PYD and CARD domain containing increases expression
multiple interactions
EXP ochratoxin A results in increased expression of PYCARD mRNA; ochratoxin A results in increased expression of PYCARD protein
N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD protein]
CTD PMID:33543323 NCBI chr 6:17,049,352...17,051,348
Ensembl chr 6:17,049,705...17,051,240
JBrowse link
G TNF tumor necrosis factor increases secretion
increases expression
EXP ochratoxin A results in increased secretion of TNF protein
ochratoxin A results in increased expression of TNF mRNA
CTD PMID:33543323 NCBI chr12:1,074,561...1,076,425
Ensembl chr12:1,074,552...1,076,425
JBrowse link
G VIM vimentin multiple interactions
increases expression
EXP CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of VIM protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of VIM protein]
ochratoxin A results in increased expression of VIM mRNA; ochratoxin A results in increased expression of VIM protein
CTD PMID:33543323 NCBI chr 2:19,671,316...19,679,367
Ensembl chr 2:19,671,316...19,679,466
JBrowse link
paraoxon term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BCHE butyrylcholinesterase decreases activity EXP Paraoxon results in decreased activity of BCHE protein CTD PMID:4631366 NCBI chr34:30,912,632...30,977,624
Ensembl chr34:30,912,632...30,977,583
JBrowse link
phorbol 13-acetate 12-myristate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G INS insulin multiple interactions EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; [Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK1 protein; [Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK3 protein CTD PMID:12639917 NCBI chr18:46,324,047...46,324,933
Ensembl chr18:46,324,041...46,325,122
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; [Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK1 protein CTD PMID:12639917 NCBI chr26:31,013,607...31,132,998
Ensembl chr26:31,013,607...31,132,998
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; [Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK3 protein CTD PMID:12639917 NCBI chr 6:18,109,184...18,115,728
Ensembl chr 6:18,109,222...18,114,425
JBrowse link
G SLC6A9 solute carrier family 6 member 9 multiple interactions
affects localization
EXP Tetradecanoylphorbol Acetate promotes the reaction [Monensin affects the localization of SLC6A9 protein]
Tetradecanoylphorbol Acetate affects the localization of SLC6A9 protein
CTD PMID:19473961 NCBI chr15:16,235,342...16,267,161
Ensembl chr15:16,235,482...16,267,933
JBrowse link
G SOD1 superoxide dismutase 1 affects response to substance EXP SOD1 protein affects the susceptibility to Tetradecanoylphorbol Acetate CTD PMID:6333936 NCBI chr31:26,540,291...26,544,212
Ensembl chr31:26,486,274...26,662,815
JBrowse link
phosphatidylinositol 3-phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Norepinephrine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; [Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate; [Norepinephrine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate; Yohimbine inhibits the reaction [[Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate] CTD PMID:15958164 NCBI chr18:13,576,966...13,611,748
Ensembl chr18:13,570,999...13,611,141
JBrowse link
rac-lactic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SCT secretin decreases abundance EXP SCT protein results in decreased abundance of Lactic Acid CTD PMID:2418308
ritonavir term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 multiple interactions EXP allicin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; hypericin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; kaempferol inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; Quercetin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir] CTD PMID:15266218 NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 increases activity EXP Ritonavir results in increased activity of NR1I2 protein CTD PMID:27732639 NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
JBrowse link
salicylamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AHR aryl hydrocarbon receptor multiple interactions EXP [salicylamide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to prochloraz; [salicylamide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to Tetrachlorodibenzodioxin CTD PMID:24389113 NCBI chr14:31,743,704...31,793,484
Ensembl chr14:31,686,170...31,791,444
JBrowse link
saquinavir term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCC2 ATP binding cassette subfamily C member 2 affects transport EXP ABCC2 protein affects the transport of Saquinavir CTD PMID:12702717 NCBI chr28:12,670,885...12,740,124
Ensembl chr28:12,670,885...12,740,740
JBrowse link
tetradecanoic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CPNE6 copine 6 decreases activity EXP Myristic Acid results in decreased activity of DHRS4 protein CTD PMID:17827741 NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
JBrowse link
UTP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G P2RY2 purinergic receptor P2Y2 multiple interactions
increases activity
EXP [Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid; [Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP] CTD PMID:10604969 NCBI chr21:24,987,568...25,009,754
Ensembl chr21:24,992,848...24,996,059
JBrowse link
vorinostat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CASQ1 calsequestrin 1 decreases expression EXP Vorinostat results in decreased expression of CASQ1 mRNA CTD PMID:27255383 NCBI chr38:22,012,060...22,020,430
Ensembl chr38:22,011,060...22,020,383
JBrowse link
G HSP70 heat shock protein 70 decreases expression EXP Vorinostat results in decreased expression of HSP70 mRNA CTD PMID:27255383 NCBI chr12:1,285,282...1,287,670 JBrowse link
G TNNI3K TNNI3 interacting kinase decreases expression EXP Vorinostat results in decreased expression of TNNI3K mRNA CTD PMID:27255383 NCBI chr 6:71,825,853...72,107,832
Ensembl chr 6:71,815,734...72,119,476
JBrowse link
VX nerve agent term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACHE acetylcholinesterase multiple interactions
decreases activity
EXP [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [VX results in decreased activity of ACHE protein] CTD PMID:16915560 NCBI chr 6:8,874,747...8,879,926
Ensembl chr 6:8,873,584...8,879,702
JBrowse link
G BCHE butyrylcholinesterase decreases activity EXP VX results in decreased activity of BCHE protein CTD PMID:16915560 NCBI chr34:30,912,632...30,977,624
Ensembl chr34:30,912,632...30,977,583
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 499
    role 499
      biological role 499
        biochemical role 459
          metabolite 450
            eukaryotic metabolite 428
              algal metabolite 36
                (+)-halomon 0
                (-)-delta-cadinol 0
                (4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoic acid + 0
                (5Z,9Z,12Z,15Z)-octadecatetraenoic acid + 0
                (6Z,9Z,12Z,15Z)-henicosa-1,6,9,12,15-pentaene 0
                (6Z,9Z,12Z,15Z)-tricosa-1,6,9,12,15-pentaene 0
                (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid + 0
                (8Z)-heptadecenal 0
                (R)-2-hydroxyglutaric acid 0
                (R,R,R)-alpha-tocopherol + 0
                1,2-dibromoethane 0
                1-methylnicotinamide + 0
                1-monopalmitoylglycerol + 0
                1-monostearoylglycerol + 0
                1-naphthyl beta-D-glucoside 0
                11(R)-HEPE 0
                11(R)-HEPE(1-) 0
                1D-myo-inositol 4-phosphate 0
                2-hydroxybutyric acid + 0
                2-hydroxypentanoic acid + 0
                2-hydroxypropanoic acid + 1
                2-oxodecanoic acid 0
                2-oxoglutarate(2-) 0
                2-palmitoylglycerol 0
                3,5-dibromocatechol 0
                3-aminopropanesulfonic acid 0
                3-bromo-4,5-dihydroxybenzoic acid 0
                3-bromo-4-hydroxybenzoic acid 0
                3-mercaptopropanoic acid 0
                3-mercaptopropionate 0
                3-phosphoglyceric acid + 0
                4-hydroxybenzoic acid + 0
                4-methyl-2-oxopentanoic acid 0
                5'-S-methyl-5'-thioadenosine 0
                5-oxo-L-proline + 0
                D-altritol + 0
                D-galactose 6-phosphate + 0
                D-glucopyranuronic acid + 0
                D-glycerate 0
                L-arabinose + 0
                L-histidine + 0
                L-homoserine + 0
                L-isoleucine + 0
                L-leucine + 0
                L-lysine + 0
                L-ornithine + 0
                L-phenylalanine + 10
                L-proline + 0
                L-serine + 0
                L-sorbose 1-phosphate 0
                L-threitol 0
                L-threonic acid + 0
                L-threonine + 0
                L-valine + 2
                O-phosphoethanolamine + 0
                acetohydroxamic acid 0
                adonixanthin 0
                agar 0
                agaropectin + 0
                all-cis-docosa-4,7,10,13,16,19-hexaenoic acid + 0
                all-cis-docosa-7,10,13,16-tetraenoic acid + 0
                alpha-D-xylose + 0
                aplysiatoxin 0
                asparagine + 1
                benzoic acid + 2
                bicyclosesquiphellandrene 0
                bis(3-aminopropyl)amine + 0
                brassicasterol + 0
                bromomethane 0
                butyl octadecanoate 0
                carrageenan + 0
                cholesterol + 0
                citramalic acid + 0
                crinosterol 0
                dainic acid A 0
                debromoaplysiatoxin 0
                decan-5-ol 0
                decanoic acid + 0
                dibromomethane 0
                dimethyl sulfide + 0
                disodium maleate 0
                dodecanoic acid + 0
                domoic acid 0
                filiforminol 0
                fucoxanthin 0
                gadoleic acid + 0
                galacturonic acid + 0
                gamma-tocopherol + 0
                glycerol + 3
                glycerol 1-phosphate + 0
                glycolate + 0
                grasshopper ketone 0
                guanine + 2
                harmalol 0
                hepoxilin B3 0
                heptacosan-1-ol 0
                heptadecanoic acid + 0
                hexadecan-1-ol + 0
                hexadecan-5-ol 0
                hexadecanoic acid + 1
                hydroxylamine + 3
                indole-4-carbaldehyde 0
                inulobiose + 0
                isodomoic acid A 0
                isofucosterol 0
                isoglutamic acid 0
                isonicotinic acid + 0
                laurebiphenyl 0
                linoleic acid + 0
                linolenic acid + 0
                ma'ilione 0
                maleic acid + 0
                methionine + 0
                methyl (Z)-7-hexadecenoate 0
                methyl cis-10-pentadecenoate 0
                methyl dihydrogen phosphate 0
                microthecin 0
                neophytadiene 0
                nonanoic acid + 0
                octadecan-1-ol + 0
                octadecanoic acid + 1
                ornithine + 0
                oxalic acid + 0
                palmitoleic acid + 0
                pantothenate + 0
                pentadecanoic acid + 0
                phloroglucinol + 0
                phlorotannin + 0
                phosphoric acid + 9
                phytol + 0
                ribofuranose + 0
                salicylic acid + 2
                sodium 4-hydroxybenzoate 0
                sodium benzoate + 0
                spirolaurenone 0
                sucrose + 0
                tetradecanoic acid + 6
                tetradecyl tetradecanoate 0
                tricosan-1-ol + 0
                xylitol + 0
paths to the root